PSMA Theranostics: Current Status and Future Directions

PSMA Theranostics: Current Status and Future Directions

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metast...

Full description

Bibliographic Details
Main Authors: Kambiz Rahbar MD, Ali Afshar-Oromieh MD, Hossein Jadvar MD, PhD, Hojjat Ahmadzadehfar MD, MSc
Format: Article
Language:English
Published: Hindawi - SAGE Publishing 2018-06-01
Series:Molecular Imaging
Online Access:https://doi.org/10.1177/1536012118776068
Description
Summary:Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177 Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.
ISSN:1536-0121

Similar Items